MYLK and bacterial infectious disease: The potential applicability of ML-7, an inhibitor of myosin light chain kinase (MLCK), in bacterial infections has not been reported to date, and studies on ML-7 are still in the in vitro phase, but its potential as a novel tigecycline adjuvant to reverse drug resistance should not be overlooked [56].